Obesity and musculoskeletal (MSK) conditions impact a major portion of the American population. With glucagon-like peptide-1 agonists (GLP-1s) rapidly transforming obesity care as well as bottom lines, it's more important than ever for employers and payers to consider strategies for sustainable impact.